DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/hft4gt/familial) has announced the addition of the "Familial Dyslipidaemia Forecast in 8 Major Markets 2016-2026" report to their offering.
Dyslipidaemia is defined as individuals with elevated triglycerides, low density lipoprotein or total cholesterol, or with lowered levels of high density lipoprotein. Many patients meet the requirements of Dyslipidaemia on more than one factor.
Dyslipidaemia can be divided into two forms: familial (primary) or acquired (secondary). Primary causes are single or multiple gene mutations and secondary causes are mainly a result of a sedentary lifestyle, with diets that consist largely of saturated fats, cholesterol and trans-fats.
Main symptoms and co-morbidities for Dyslipidaemia include:
- Diabetes & metabolic syndrome
- Coronary artery disease
- Peripheral arterial disease
- Aortic stenosis (familial)
Reason to buy:
- Able to quantify patient populations in global Dyslipidaemia's market to target the development of future products, pricing strategies and launch plans.
- Gain further insight into the prevalence of the subdivided types of Dyslipidaemia and identify patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Provide a level of understanding on the impact from specific co-morbid conditions on Dyslipidaemia's prevalent population.
- Identify sub-populations within Dyslipidaemia which require treatment.
Gain an understanding of the specific markets that have the largest
number of Dyslipidaemia patients.
Key Topics Covered:
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key Co-morbid Conditions/Features Associated with the Disease
8. Methodology for Quantification of Patient Numbers
9. Top-Line Prevalence for Dyslipidaemia
10. Secondary vs. Primary Dyslipidaemia
11. Abbreviations used in the Report
12. Patient-Based Offering
13. Online Pricing Data and Platforms
For more information visit http://www.researchandmarkets.com/research/hft4gt/familial